59 related articles for article (PubMed ID: 35507079)
1. Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures.
Guo D; Zhang S; Gao Y; Shi J; Wang X; Zhang Z; Zhang Y; Wang Y; Zhao K; Li M; Wang A; Wang P; Gou Y; Zhang M; Liu M; Zhang Y; Chen R; Sun J; Wang S; Wu X; Liang Z; Chen J; Lang J
Cell Biosci; 2023 Jul; 13(1):139. PubMed ID: 37525249
[TBL] [Abstract][Full Text] [Related]
2. EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells.
Shen X; Jin X; Fang S; Chen J
Cell Mol Biol Lett; 2023 Jul; 28(1):53. PubMed ID: 37420173
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Huang W; Ran R; Shao B; Li H
Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
[TBL] [Abstract][Full Text] [Related]
6. The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas.
Matsuura H; Miyamoto M; Hada T; Ishibashi H; Iwahashi H; Kakimoto S; Suzuki R; Ito T; Suminokura J; Tsuda H; Takano M
Arch Gynecol Obstet; 2022 Dec; 306(6):2133-2142. PubMed ID: 35507079
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
Hongo T; Yamamoto H; Jiromaru R; Yasumatsu R; Kuga R; Nozaki Y; Hashimoto K; Matsuo M; Wakasaki T; Tamae A; Taguchi K; Toh S; Masuda M; Nakagawa T; Oda Y
Mod Pathol; 2021 Nov; 34(11):1966-1978. PubMed ID: 34218257
[TBL] [Abstract][Full Text] [Related]
10. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
12. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
[TBL] [Abstract][Full Text] [Related]
14. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Oda K; Hamanishi J; Matsuo K; Hasegawa K
Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
[TBL] [Abstract][Full Text] [Related]
15. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]